var data={"title":"Vasopressin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Vasopressin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7145?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=vasopressin-drug-information\" class=\"drug drug_general\">see &quot;Vasopressin: Drug information&quot;</a> and <a href=\"topic.htm?path=vasopressin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Vasopressin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559967\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Pitressin Synthetic [DSC];</li>\n      <li>Vasostrict</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233595\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Pressyn;</li>\n      <li>Pressyn AR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062878\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidiuretic Hormone Analog</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Hormone, Posterior Pituitary</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11445264\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Note:</b> Units of measure vary by indication and age (ie, milliunits/kg/<b>hour</b>, units/kg/<b>hour</b>, milliunits/kg/minute, units/kg/minute; <b>units/minute</b>, units/<b>hour</b>); extra precautions should be taken.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cardiac surgery (complex procedure; eg, Norwood; arterial switch); post-bypass:</b> Limited data available: Continuous IV infusion: Mean reported dose range: 0.3 to 0.5 milliunits/kg/minute, titrated to hemodynamic goals (Alten 2012; Burton 2011). Dosing based on experience in 37 neonates (n=19 in vasopressin group) which showed a mean infusion rate: 0.3 milliunits/kg/minute (range: 0.08 to 1 milliunit/kg/minute) was associated with decreased catecholamine use and significant reduction in fluid resuscitation during first 24 hours after surgery compared to the control group (Alten 2012); a retrospective report of 28 neonates with refractory hemodynamic instability after Norwood palliation showed improvement in urine output, SBP, and pH markers with vasopressin at a mean infusion rate of 0.5 milliunits/kg/minute (Burton 2011). <b>Note:</b> Hyponatremia reported frequently; monitor serum Na (Alten 2012; Davalos 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Hypotension (initial therapy):</b> Very limited data available (Rios 2014): ELBW neonates (GA &le;30 weeks): Continuous IV infusion: Reported range: 0.17 to 0.67 milliunits/kg/minute (0.01 to 0.04 units/kg/<b>hour</b>); dosing initiated at low end of range and titrated at 20 minute intervals in 0.17 milliunits/kg/minute (0.01 units/kg/<b>hour</b>) increments. Dosing based on a prospective, randomized, double-blind trial comparing vasopressin and dopamine as initial therapy in 20 hypotensive ELBW neonates (vasopressin treatment group, n=10; mean GA: 25.7 weeks; PNA: &lt;24 hours; mean birth weight: 640 g) with a control group of 50 normotensive ELBW neonates; primary efficacy outcomes were similar in both treatment groups; other findings showed that subjects in the vasopressin group received significantly fewer surfactant doses and had a lower mean PaCO<sub>2</sub>; and unlike the dopamine group, tachycardia was not observed in the vasopressin group (Rios 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Persistent pulmonary hypertension of the newborn (PPHN), refractory:</b> Very limited data available: GA &ge;37 weeks: Continuous IV infusion: Initial: 0.1 milliunits/kg/minute, increase in 0.1 milliunits/kg/minute increments every hour as needed for clinical response to a maximum dose of 1.2 milliunits/kg/minute; dosing based on a case series in 10 neonates (GA &ge;37 weeks; birth weight &ge;2.2 kg) which showed significant improvement in oxygenation index, blood pressure, and urine output and a reduction in iNO dose (Mohamed 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Shock; vasodilatory with refractory hypotension unresponsive to fluid resuscitation and exogenous catecholamines:</b> Limited data available; dosing regimens and efficacy results variable: Continuous IV infusion: 0.17 to 10 milliunits/kg/minute (0.01 to 0.6 units/kg/<b>hour</b>) have been used; doses were initiated at the lower end of the range and titrated to effect in most studies. Dosing based on retrospective reviews and case reports that have shown increases in arterial blood pressure and urine output and also allowed for dosage reductions of additional vasopressors (Bidegain 2010; Brierley 2009; Choong 2008; Ikegami 2010; Meyer 2008). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062871\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=vasopressin-drug-information\" class=\"drug drug_general\">see &quot;Vasopressin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Note:</b> Units of measure vary by indication and age (ie, milliunits/kg/<b>hour</b>, units/kg/<b>hour</b>, milliunits/kg/minute, units/kg/minute; <b>units/minute</b>, units/<b>hour</b>); extra precautions should be taken.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Diabetes insipidus: Note:</b> Highly variable dosage; titrate dosage based upon serum and urine sodium and osmolality in addition to fluid balance and urine output. Children and Adolescents: IM, SubQ: 2.5 to 10 units 2 to 4 times daily (Kliegman 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Central diabetes insipidus:</i> Limited data available: Infants, Children, and Adolescents: Continuous IV infusion: Initial: 0.5 milliunits/kg/<b>hour</b>; titrate upward in 0.5 milliunits/kg/<b>hour</b> increments at approximately 10-minute intervals to target urine output (suggested output target: &lt;2 mL/kg/hour) (Sperling 2014; Wise-Faberowski 2004); infusion rates up to 10 milliunits/kg/<b>hour</b> have been reported (Alharfi 2013). <b>Note:</b> Use in conjunction with fluid therapy, monitor urine output and specific gravity, serum and urine electrolytes (primarily Na), and plasma osmolality.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Cadaveric organ donations (hormone replacement therapy):</b> Limited data available (Nakagawa/NATCO Guidelines 2008): Infants, Children, and Adolescents: Continuous IV infusion: Initial: 0.5 to 1 milliunits/kg/<b>hour</b>; titrate dose to maintain targeted urine output. In a retrospective case-controlled study (n=34, age: 8.2 &plusmn; 6.2 years), a mean dose of 41 milliunits/kg/<b>hour</b> was reported with a range of 0.2 milliunits/kg/<b>hour</b> to 150 milliunits/kg/<b>hour</b> (Katz 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>GI hemorrhage:</b> Limited data available: Children and Adolescents: Continuous IV infusion: Initial: 2 to 5 milliunits/kg/minute; titrate dose as needed; maximum dose: 10 milliunits/kg/minute (Kliegman 2007, Tuggle 1988); usual adult dosing range is 0.2 to 0.4 <b>units/minute</b> up to a maximum rate of 0.8 <b>units/minute</b> (AASLD [Garcia-Tsao 2007]). <b>Note:</b> Higher doses have not been associated with greater efficacy but have been associated with increased risk of complications (Tuggle 1988). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Pulseless arrest, ventricular fibrillation, ventricular tachycardia:</b> Limited data available: Infants, Children, and Adolescents: IV: 0.4 units/kg as a single dose after traditional resuscitation methods and at least two doses of epinephrine have been administered. <b>Note:</b> Due to insufficient evidence, no formal recommendations for or against the routine use of vasopressin during pediatric cardiac arrest are provided (Duncan 2009; Mann 2002; PALS 2010). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Vasodilatory shock with hypotension unresponsive to fluid resuscitation and exogenous catecholamines:</b> Limited data available; efficacy results have varied (SCCM [Dellinger 2013]): Infants, Children, and Adolescents: Continuous IV infusion: 0.17 to 8 milliunits/kg/minute (0.01 to 0.48 units/kg/<b>hour</b>) has been used; dosing based on retrospective reviews and case reports that have shown increases in arterial blood pressure and urine output and also allowed for dosage reductions of additional vasopressors (Brierley 2009; Choong 2008; Meyer 2008). The only double-blind, placebo-controlled trial (n=65, age: 3 to 14 years) evaluated a dose of 0.5 to 2 milliunits/kg/minute (0.03 to 0.12 units/kg/<b>hour</b>) at multiple centers and found no significant difference in the time to reach hemodynamic stability and a trend toward increased mortality in the vasopressin group was noted. Based on these findings, the authors did not recommend routine use of vasopressin (Choong 2009). <b>Note:</b> Abrupt discontinuation of infusion may result in hypotension; to discontinue, gradually taper infusion. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Central diabetes insipidus: Note:</b> Dosage is highly variable; titrated based on serum and urine sodium and osmolality in addition to fluid balance and urine output. Use of vasopressin is impractical for chronic therapy. IM, SubQ: 5 to 10 units 2 to 4 times daily as needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Vasodilatory shock:</b> IV: <b>Note:</b> Dosage provided is empirical; titrate to lowest dose compatible with an acceptable response. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Post-cardiotomy shock:</i> Initial: 0.03 units per minute. If the target blood pressure response is not achieved, titrate up by 0.005 units per minute at 10- to 15-minute intervals (maximum dose: 0.1 units per minute). After target blood pressure has been maintained for 8 hours without the use of catecholamines, taper by 0.005 units per minute every hour as tolerated to maintain target blood pressure.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Septic shock:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">\n      <i>Surviving Sepsis Campaign recommendations:</i> 0.03 units per minute added to norepinephrine to raise MAP to target or to decrease norepinephrine dose. Doses &gt;0.03 units per minute may have more cardiovascular side effects and should only be reserved for salvage therapy (ie, failure to achieve MAP goal with other vasopressors) (SCCM [Dellinger 2013]). If vasopressin is used concurrently with other catecholamines (eg, norepinephrine), patients may experience hypotension if vasopressin is discontinued first (Bauer 2010). To prevent subsequent hypotension after withdrawal of vasopressors, some experts recommend slowly tapering vasopressin (eg, reducing by 0.01 units per minute every 30 minutes) <b>after</b> the catecholamine(s) are discontinued until no longer required.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">\n      <i>Manufacturer's labeling:</i> Initial: 0.01 units per minute. If the target blood pressure response is not achieved, titrate up by 0.005 units per minute at 10- to 15-minute intervals. Maximum dose: 0.07 units per minute. After target blood pressure has been maintained for 8 hours without the use of catecholamines, taper by 0.005 units per minute every hour as tolerated to maintain target blood pressure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233569\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pitressin Synthetic: 20 units/mL (1 mL [DSC]) [contains chlorobutanol (chlorobutol)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 units/mL (0.5 mL [DSC], 1 mL [DSC], 10 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vasostrict: 20 units/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vasostrict: 20 units/mL (10 mL) [contains chlorobutanol (chlorobutol)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 40 units/100 mL in NaCl 0.9% (100 mL); 50 units/50 mL in NaCl 0.9% (50 mL); 60 units/100 mL in NaCl 0.9% (100 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233553\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062883\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IM, SubQ: Administer without further dilution. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Continuous IV infusion: Dilute prior to administration. Infusion through central line is strongly recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Initiate phentolamine (or alternative antidote) (see Management of Drug Extravasations for more details).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233588\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Store intact vials between 2&deg;C and 8&deg;C (36&deg;F and 46&deg;F). Do not freeze.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vasostrict: May also remove intact vials from refrigeration and store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F) for up to 12 months or manufacturer expiration date, whichever is earlier (indicate date of removal on the vial or note the manufacturer expiration date, whichever is earlier). After initial entry into the 10 mL vial, opened vial must be refrigerated; discard 30 days after first puncture. Discard unused diluted solution (in D5W or NS) after 18 hours at room temperature or 24 hours under refrigeration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062882\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitressin (synthetic): Treatment of diabetes insipidus (FDA approved in pediatric patients [age not specified] and adults) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vasostrict: To increase blood pressure in patients with vasodilatory shock (eg, postcardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Has also been used as an adjunct in the treatment of acute massive GI hemorrhage; treatment of pulseless arrest, ventricular fibrillation or tachycardia, and asystole/pulseless electrical activity; systemic hypotension and persistent pulmonary hypertension in neonates; and cadaveric organ donation </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Although abdominal roentgenography and postoperative abdominal distention (prevention/treatment) are included as FDA approved uses in the manufacturer's prescribing information, there is insufficient evidence to recommend the use of vasopressin for these indications. A data review determined that the evidence was insufficient to recommend the use of vasopressin in the setting of postoperative adynamic ileus following abdominal surgery (Traut 2008). Vasopressin has been removed from the adult cardiac arrest algorithm; based on the 2015 American Heart Association (AHA) Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care, vasopressin offers no advantage as a substitute for epinephrine and no advantage when used in combination with epinephrine as a substitute for standard dose epinephrine in adult cardiac arrest (ventricular fibrillation [VF]/pulseless ventricular tachycardia [pVT], asystole, or pulseless electrical activity [PEA]). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9517809\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Vasopressin may be confused with desmopressin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (IV or intraosseous administration) among its list of drugs which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Use care when prescribing and/or administering vasopressin solutions. Close attention should be given to concentration of solution, route of administration, dose, and rate of administration (units/minute, units/kg/minute, units/kg/hour).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233627\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Angina pectoris, atrial fibrillation, bradycardia, cardiac arrest, cardiac arrhythmia, ischemic heart disease, limb ischemia (distal), localized blanching, low cardiac output, myocardial infarction, right heart failure, shock, vasoconstriction (peripheral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Headache (pounding), vertigo </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Circumoral pallor, diaphoresis, gangrene of skin or other tissues, skin lesion (ischemic), urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Hyponatremia, hypovolemic shock, water intoxication</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal cramps, flatulence, mesenteric ischemia, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Decreased platelet count, hemorrhage (intractable)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased serum bilirubin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Tremor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Renal insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Bronchoconstriction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233577\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to vasopressin or any component of the formulation; hypersensitivity to chlorobutanol (Vasostrict only); uncorrected chronic nephritis with nitrogen retention (Pitressin Synthetic only)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233557\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Vesicant; ensure proper needle or catheter placement prior to and during infusion. Extravasation may lead to severe vasoconstriction and localized tissue necrosis; also, gangrene of extremities, tongue, and ischemic colitis. Avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Water intoxication: May cause water intoxication; early signs include drowsiness, listlessness, and headache; these should be recognized to prevent coma and seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma: Use with caution in patients with asthma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease, including arteriosclerosis; may worsen cardiac output.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Goiter: Use with caution in patients with a goiter with cardiac complications.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Migraine: Use with caution in patients with a history of migraines.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Use with caution in patients with a history of seizure disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vascular disease: Use with caution in patients with vascular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Caution elderly patients not to increase their fluid intake beyond that sufficient to satisfy their thirst in order to avoid water intoxication and hyponatremia; under experimental conditions, the elderly have shown to have a decreased responsiveness to vasopressin with respect to its effects on water homeostasis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46131507\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May cause hyponatremia; frequency not well-defined in pediatric patients and may vary based on indication. In young pediatric patients (mean age: 5.2 months; including neonates) who received a vasopressin infusion for hemodynamic instability following complex cardiac surgery, the observed incidence of hyponatremia (defined as serum Na &lt;135 mEq/L) was statistically higher in the vasopressin group than the control (48% vs 17%, p=0.004) and the decrease in serum sodium concentration was significantly greater (9.9 mEq/L vs 7.5 mEq/L, p=0.009); it was also observed that the decrease in the serum Na was more rapid in the vasopressin group (Davalos 2013). With other uses in pediatric patients, hyponatremia has not been characterized; monitor fluid balance, serum Na and urine output closely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300210\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233562\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12876&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233590\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Ethanol may decrease the antidiuretic effect. Management: Avoid ethanol.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233564\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233580\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Vasopressin may produce tonic uterine contractions; however, doses sufficient for diabetes insipidus are not likely to produce this effect.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062877\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Specific monitoring determined by indication and may include: Blood pressure, heart rate, fluid intake and output, urine specific gravity, urine and serum osmolality; serum and urine sodium: Hemoglobin and hematocrit (GI bleeding). Consult individual institutional policies and procedures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062881\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Vasopressin concentration:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Basal: &lt;4 pg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Water deprivation: 10 pg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Shock: 100 to 1,000 pg/mL (biphasic response)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233556\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Vasopressin stimulates a family of arginine vasopressin (AVP) receptors, oxytocin receptors, and purinergic receptors (Russell 2011). Vasopressin, at therapeutic doses used for vasodilatory shock, stimulates the AVPR1a (or V1) receptor and increases systemic vascular resistance and mean arterial blood pressure; in response to these effects, a decrease in heart rate and cardiac output may be seen. When the AVPR2 (or V2) receptor is stimulated, cyclic adenosine monophosphate (cAMP) increases which in turn increases water permeability at the renal tubule resulting in decreased urine volume and increased osmolality. Vasopressin, at pressor doses, also causes smooth muscle contraction in the GI tract by stimulating muscular V1 receptors and release of prolactin and ACTH via AVPR1b (or V3) receptors.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233576\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nasal: 1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: Vasopressor effect: Rapid with peak effect occurring within 15 minutes of initiation of continuous IV infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Nasal: 3 to 8 hours; IM, SubQ: Antidiuretic: 2 to 8 hours; IV: Vasopressor effect: Within 20 minutes after IV infusion terminated </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: None from GI tract, destroyed by trypsin in GI tract, must be administered parenterally</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic, renal (inactive metabolites)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: IM, IV, SubQ: 10 to 20 minutes (apparent half-life: &le;10 minutes) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Nasal: Urine; SubQ: Urine (5% as unchanged drug) after 4 hours; IV: Urine (~6% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16324084\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Vasopressin-Sodium Chloride Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40UT/100ML 0.9% (100 mL): $346.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50UT/50ML 0.9% (50 mL): $436.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60UT/100ML 0.9% (100 mL): $629.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Vasostrict Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 units/mL (1 mL): $182.62</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038856\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>C Pressin (IN);</li>\n      <li>Encrise (BR);</li>\n      <li>Farpresin (ID);</li>\n      <li>Hemopressin (PK);</li>\n      <li>Novopressina-V (AR);</li>\n      <li>Petresin (LK);</li>\n      <li>Pitressin (AU, GR, HK, IE, NZ, TW);</li>\n      <li>Vasosin (TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alharfi IM, Stewart TC, Foster J, Morrison GC, Fraser DD. Central diabetes insipidus in pediatric severe traumatic brain injury. <i>Pediatr Crit Care Med</i>. 2013;14(2):203-209.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/23314181 /pubmed\" target=\"_blank\" id=\"23314181 \">23314181 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alten JA, Borasino S, Toms R, Law MA, Moellinger A, Dabal RJ. Early initiation of arginine vasopressin infusion in neonates after complex cardiac surgery. <i>Pediatr Crit Care Med</i>. 2012;13(3):300-304.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/21926664 /pubmed\" target=\"_blank\" id=\"21926664 \">21926664 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bauer SR, Aloi JJ, Ahrens CL, Yeh JY, Culver DA, Reddy AJ. Discontinuation of vasopressin before norepinephrine increases the incidence of hypotension in patients recovering from septic shock: a retrospective cohort study. <i>J Crit Care</i>. 2010;25(2):362.e7-362.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/19926252 /pubmed\" target=\"_blank\" id=\"19926252 \">19926252 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bidegain M, Greenberg R, Simmons C, et al, &quot;Vasopressin for Refractory Hypotension in Extremely Low Birth Weight Infants,&quot; <i>J Pediatr</i>, 2010, 157(3):502-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/20727442/pubmed\" target=\"_blank\" id=\"20727442\">20727442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brierley J, Carcillo JA, Choong K, et al, &quot;Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: 2007 Update From the American College of Critical Care Medicine,&quot; <i>Crit Care Med</i>, 2009, 37(2):666-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/19325359/pubmed\" target=\"_blank\" id=\"19325359\">19325359</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burton GL, Kaufman J, Goot BH, da Cruz EM. The use of arginine vasopressin in neonates following the Norwood procedure. <i>Cardiol Young</i>. 2011;21(5):536-544.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/21554826 /pubmed\" target=\"_blank\" id=\"21554826 \">21554826 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Choong K and Kissoon N, &quot;Vasopressin in Pediatric Shock and Cardiac Arrest,&quot; <i>Pediatr Crit Care Med</i>, 2008, 9(4):372-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/18496412/pubmed\" target=\"_blank\" id=\"18496412\">18496412</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Choong K, Bohn D, Fraser DD, et al, &quot;Vasopressin in Pediatric Vasodilatory Shock: A Multicenter Randomized Controlled Trial,&quot; <i>Am J Respir Crit Care Med</i>, 2009, 180(7):632-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/19608718/pubmed\" target=\"_blank\" id=\"19608718\">19608718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davalos MC, Barrett R, Seshadri S, et al. Hyponatremia during arginine vasopressin therapy in children following cardiac surgery. <i>Pediatr Crit Care Med</i>. 2013;14(3):290-297.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/23392370 /pubmed\" target=\"_blank\" id=\"23392370 \">23392370 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. <i>Crit Care Med</i>. 2013;41(2):580-637.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/23353941 /pubmed\" target=\"_blank\" id=\"23353941 \">23353941 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Duncan JM, Meaney P, Simpson P, et al, &quot;Vasopressin for In-Hospital Pediatric Cardiac Arrest: Results From the American Heart Association National Registry of Cardiopulmonary Resuscitation,&quot; <i>Pediatr Crit Care Med</i>, 2009, 10(2):191-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/19188873/pubmed\" target=\"_blank\" id=\"19188873\">19188873</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garcia-Tsao G, Sanyal AJ, Grace ND, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. <i>Hepatology</i>. 2007;46(3):922-938.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/17879356 /pubmed\" target=\"_blank\" id=\"17879356 \">17879356 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hodges BM and Fraser G, &quot;Vasopressin for Vasodilatory Shock,&quot; <i>Hosp Pharm</i>, 2002, 37(11):1149-57.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ikegami H, Funato M, Tamai H, et al, &quot;Low-Dose Vasopressin Infusion Therapy for Refractory Hypotension in ELBW Infants,&quot; <i>Pediatr Int</i>, 2010, 52(3):368-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/19793209/pubmed\" target=\"_blank\" id=\"19793209\">19793209</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Katz K, Lawler J, Wax J, et al, &quot;Vasopressin Pressor Effects in Critically Ill Children During Evaluation for Brain Death and Organ Recovery,&quot; <i>Resuscitation</i>, 2000, 47(1):33-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/11004379/pubmed\" target=\"_blank\" id=\"11004379\">11004379</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleinman ME, Chameides L, Schexnayder SM, et al, &quot;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&quot; <i>Circulation</i>, 2010, 122(18 Suppl 3):S876-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/20956230/pubmed\" target=\"_blank\" id=\"20956230\">20956230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koshman SL, Zed PJ, and Abu-Laban RB, &quot;Vasopressin in Cardiac Arrest,&quot; <i>Ann Pharmacother</i>, 2005, 39(10):1687-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/16118265/pubmed\" target=\"_blank\" id=\"16118265\">16118265</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liedel JL, et al, &quot;The Successful Use of Vasopressin in Children With Hypotension,&quot; <i>Crit Care Med</i>, 2001, 29(12):A63.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mann K, Berg RA, and Nadkarni V, &quot;Beneficial Effects of Vasopressin in Prolonged Pediatric Cardiac Arrest: A Case Series,&quot; <i>Resuscitation</i>, 2002, 52(2): 149-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/11841882/pubmed\" target=\"_blank\" id=\"11841882\">11841882</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meyer S, Gortner L, McGuire W, et al, &quot;Vasopressin in Catecholamine-Refractory Shock in Children,&quot; <i>Anaesthesia</i>, 2008, 63(3):228-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/18081903/pubmed\" target=\"_blank\" id=\"18081903\">18081903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mohamed A, Nasef N, Shah V, McNamara PJ. Vasopressin as a rescue therapy for refractory pulmonary hypertension in neonates: case series. <i>Pediatr Crit Care Med</i>. 2014;15(2):148-154.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/24141655 /pubmed\" target=\"_blank\" id=\"24141655 \">24141655 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nakagawa TA, &quot;Pediatric Donor Management Guidelines. NATCO, The Organization for Transplant Professionals,&quot; 2008, UpToDate&reg;, Basow DS, ed, Waltham, MA: UpToDate&reg;, 2011. Available at http://www.uptodate.com</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pitressin synthetic (vasopressin) [prescribing information]. Rochester, MI: JHP Pharmaceuticals LLC; October 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rios DR, Kaiser JR. Vasopressin versus dopamine for treatment of hypotension in extremely low birth weight infants: a randomized, blinded pilot study. <i>J Pediatr</i>. 2015;166(4):850-855.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/25641242 /pubmed\" target=\"_blank\" id=\"25641242 \">25641242 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rios DR, Moffett BS, Kaiser JR. Trends in pharmacotherapy for neonatal hypotension. <i>J Pediatr</i>. 2014;165(4):697-701.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/25039051 /pubmed\" target=\"_blank\" id=\"25039051 \">25039051 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosendale JD, Kauffman HM, McBride MA, et al, &quot;Aggressive Pharmacologic Donor Management Results in More Transplanted Organs,&quot; <i>Transplantation</i>, 2003, 75(4):482-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/12605114/pubmed\" target=\"_blank\" id=\"12605114\">12605114</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenzweig EB, Starc TJ, Chen JM, et al, &quot;Intravenous Arginine-Vasopressin in Children With Vasodilatory Shock After Cardiac Surgery,&quot; <i>Circulation</i>, 1999, 100(19 Suppl):II182-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/10567301/pubmed\" target=\"_blank\" id=\"10567301\">10567301</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sperling MA, ed. <i>Pediatric Endocrinology</i>. 4th ed. Canada: Elsevier; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Traut U, Br&uuml;gger L, Kunz R, et al. Systemic prokinetic pharmacologic treatment for postoperative adynamic ileus following abdominal surgery in adults. <i>Cochrane Database Syst Rev</i>. 2008;(1):CD004930.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/18254064 /pubmed\" target=\"_blank\" id=\"18254064 \">18254064 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tuggle DW, Bennett KG, Scott J, et al, &quot;Intravenous Vasopressin and Gastrointestinal Hemorrhage in Children,&quot; <i>J Pediatr Surg</i>, 1988, 23(7):627-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/3144593/pubmed\" target=\"_blank\" id=\"3144593\">3144593</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    UNOS, &quot;Critical Pathway for Donation After Cardiac Death.&quot; Available at http://www.unos.org/docs/Critical_Pathway_DCD_Donor.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vasostrict (vasopressin) [prescribing information]. Spring Valley, NY: Par Pharmaceutical Companies Inc; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wise-Faberowski L, Soriano SG, Ferrari L, et al, &quot;Perioperative Management of Diabetes Insipidus in Children,&quot; <i>J Neurosurg Anesthesiol</i>, 2004, 16(3):220-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vasopressin-pediatric-drug-information/abstract-text/15211159/pubmed\" target=\"_blank\" id=\"15211159\">15211159</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12876 Version 96.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9559967\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F233595\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1062878\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11445264\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1062871\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F233569\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F233553\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1062883\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F233588\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1062882\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9517809\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F233627\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F233577\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F233557\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F46131507\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300210\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F233562\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F233590\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F233564\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F233580\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1062877\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1062881\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F233556\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F233576\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16324084\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038856\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12876|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=vasopressin-drug-information\" class=\"drug drug_general\">Vasopressin: Drug information</a></li><li><a href=\"topic.htm?path=vasopressin-patient-drug-information\" class=\"drug drug_patient\">Vasopressin: Patient drug information</a></li></ul></div></div>","javascript":null}